Scientist/Senior Scientist, LNP Discovery at Prime Medicine

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

PhD in Biomedical/Chemical Engineering, Biochemistry, or related field with 0-2 years of relevant experience (or BS+8 years, MS+6 years)
Experience with lipid nanoparticle (LNP) formulation, QC, and characterization techniques
Hands-on experience with mouse handling, dosing, and tissue collection; intratracheal delivery (e.g., broncoscope) strongly preferred
Familiarity/experience with molecular biology techniques (e.g., qPCR, DNA sequencing, mammalian cell culture, and flow cytometry preferred)
Strong organizational and critical thinking skills, attention to detail
Ability to work both independently and as part of a collaborative team
Excellent communication and interpersonal skills to thrive in a cross-functional setting
Onsite 5 days a week in Cambridge, MA

Responsibilities

Design and formulate LNPs using microfluidics; characterize using DLS, zeta potential, pKa, and Ribogreen assays
Execute and support in vivo studies focused on pulmonary delivery of LNP formulations including intratracheal delivery in preclinical models
Collaborate with internal teams on study design, execution, data collection, and interpretation
Support downstream analyses using flow cytometry and molecular biology techniques
Collaborate cross-functionally to integrate in vivo findings into delivery platform development
Present data in written reports and oral presentations

Skills

LNP formulation

LNP characterization

in vivo delivery

mouse models

pulmonary delivery

Prime Editor RNA

non-viral delivery

gene editing

Prime Medicine

Gene editing technology for genetic diseases

About Prime Medicine

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, it emphasizes collaboration with research institutions and pharmaceutical companies to advance its technology and bring it to market through licensing agreements and partnerships. The leadership team has extensive experience in developing innovative medicines, and the company is committed to enhancing its technological capabilities.

Cambridge, MassachusettsHeadquarters

2019Year Founded

$306.4MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Flexible Work Hours

Risks

Intellectual property disputes may lead to costly legal battles and delays.

The competitive landscape in gene editing is intensifying, challenging Prime Medicine's market position.

Reliance on partnerships exposes Prime Medicine to risks if collaborations don't meet expectations.

Differentiation

Prime Editing offers precise DNA modifications without double-stranded breaks, unlike CRISPR.

Prime Medicine's technology can correct faulty DNA segments, restoring normal genetic function.

The company collaborates with top-tier partners like Bristol Myers Squibb for strategic growth.

Upsides

Prime Medicine secured $244.6M to advance its genetic therapies and pipeline.

The partnership with Bristol Myers Squibb includes potential milestone payments over $3.5 billion.

Growing interest in gene editing for rare diseases boosts investment and collaboration opportunities.

Land your dream remote job 3x faster with AI

Try Jobo Free